Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving BRAFi ± MEKi. In this study, we evaluated the imp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Reger de Moura, Coralie, Vercellino, Laetitia, Jouenne, Fanélie, Baroudjian, Barouyr, Sadoux, Aurélie, Louveau, Baptiste, Delyon, Julie, Serror, Kevin, Goldwirt, Lauriane, Merlet, Pascal, Bouquet, Fanny, Battistella, Maxime, Lebbé, Céleste, Mourah, Samia
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2019
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931208/
https://ncbi.nlm.nih.gov/pubmed/31874374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados